Trial Profile
RESTORE (Raptiva (Efalizumab) Evaluation of Safety and Treatment Optimization Registry) Observational, Open-Label, Multi-Centre, Phase IV Study of Subcutaneously Administered Raptiva (Efalizumab) in the Treatment of Adult Patients With Moderate to Severe Chronic Plaque Psoriasis Who Are Candidates for Treatment With Raptiva.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2018
Price :
$35
*
At a glance
- Drugs Efalizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Acronyms RESTORE
- Sponsors EMD Serono; Merck KGaA
- 22 Dec 2009 Planned end date changed from 1 May 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 06 Mar 2009 New trial record